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Abstract
Objectives
To investigate disease history before A(H1N1)pdm09 vaccination as a risk factor for
narcolepsy.
Methods
Case-control study in Sweden. Cases included persons referred for a Multiple Sleep
Latency Test between 2009 and 2010, identified through diagnostic sleep centres and con-
firmed through independent review of medical charts. Controls, selected from the total pop-
ulation register, were matched to cases on age, gender, MSLT-referral date and county of
residence. Disease history (prescriptions and diagnoses) and vaccination history was col-
lected through telephone interviews and population-based healthcare registers. Conditional
logistic regression was used to investigate disease history before A(H1N1)pdm09 vaccina-
tion as a risk-factor for narcolepsy.
Results
In total, 72 narcolepsy cases and 251 controls were included (range 3–69 years mean19-
years). Risk of narcolepsy was increased in individuals with a disease history of nervous
system disorders (OR range = 3.6–8.8) and mental and behavioural disorders (OR = 3.8,
95% CI 1.6–8.8) before referral. In a second analysis of vaccinated individuals only, nearly
all initial associations were no longer statistically significant and effect sizes were smaller
(OR range = 1.3–2.6). A significant effect for antibiotics (OR = 0.4, 95% CI 0.2–0.8) and a
marginally significant effect for nervous system disorders was observed. In a third case-
only analysis, comparing cases referred before vaccination to those referred after;
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prescriptions for nervous system disorders (OR = 26.0 95% CI 4.0–170.2) and ADHD (OR =
35.3 95% CI 3.4–369.9) were statistically significant during the vaccination period, suggest-
ing initial associations were due to confounding by indication.
Conclusion
The findings of this study do not support disease history before A(H1N1)pdm09 vaccination
as a risk factor for narcolepsy.
Introduction
Between October 2009 and March 2010 during the A(H1N1)pdm09 influenza pandemic, vac-
cination with AS03-adujvanted A(H1N1)pdm09 vaccine was carried out in Sweden with an
estimated coverage of 60% [1]. Following the vaccination campaign, several cases of narcolepsy
were reported to the Swedish Medical Products Agency, leading to concern over a possible
association between the vaccine and narcolepsy. This notion was subsequently confirmed in a
registry study in children under 19-years [2]. Similar associations between vaccination and nar-
colepsy have been reported in several studies from other countries [3–7]. It is still unclear if
this association is linked to the AS03 adjuvant used in the A(H1N1)pdm09 vaccine or particu-
lar features of the specific influenza antigen component [8, 9].
In 2014, the International Classification of Sleep Disorders (ICSD-3) introduced two new
terms for the classification of narcolepsy: Type-1 narcolepsy and Type-2 narcolepsy [10]. Prior
to this point, narcolepsy was known as either narcolepsy with cataplexy or narcolepsy without
cataplexy [11]. Narcolepsy has been shown to be strongly associated with the
HLA-DQB106:02 allele and the loss of hypothalamic hypocretin (orexin)-producing neurons
results in the development of narcolepsy [12–14]. This has led to the speculation that narco-
lepsy may be an immune mediated disease [12, 15]. Additional findings from genetic studies
support the possibility that vaccinations could act as environmental triggers for narcolepsy [12,
16–18]. In addition to underlying genetic susceptibility, epidemiological and seroepidemiologi-
cal studies have looked at the role of chronic diseases [12, 19, 20], streptococcal infection as a
trigger [21, 22] and that infection with H1N1 could itself play a role in the development of nar-
colepsy [22–25]. However the role of disease history, e.g. chronic diseases, cancer, respiratory
diseases, bacterial diseases, viral diseases and mental/behavioural disorders for the association
between A(H1N1)pdm09 vaccine and narcolepsy has rarely been studied. With an increasing
body of evidence now linking narcolepsy with an autoimmune reaction and potentially strepto-
coccal and H1N1 infection, it is therefore relevant to study disease history, especially autoim-
mune manifestations and infections, to determine any evidence of such an association.
Methods
Study setting
This was a nationwide retrospective case-control study with a source population of approxi-
mately 9.4 million people between 2009 and 2010 [26]. It is built upon original methodology as
part of the Vaccine Adverse Event Surveillance and Communication (VAESCO), European
Centre of Disease Control [27].
Case and control identification
Cases were identified through diagnostic sleep centres and/or neurophysiology labs in Sweden,
with the six largest centres (out of seven nationwide) participating. The centres provided a list
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of potential cases i.e. a list of individuals referred for a Multiple Sleep Latency Test (MSLT)
during the study period, 1st January 2009 and 31st December 2010. Of the 431 potential cases,
142 received a primary diagnosis of narcolepsy by the initial referring clinician. Karolinska
Institutet contacted these preliminarily diagnosed cases to request their participation in the
study.
Of the 142 preliminary diagnosed cases, 27 refused participation and 18 were not contact-
able. The medical charts of the remaining 97 subjects were reviewed by a neurologist blinded to
A(H1N1)pdm09 vaccination status. Consequently, 17 subjects were excluded as they were dis-
covered to have an MSLT referral date outside the study period and eight did not have a diag-
nosis of narcolepsy according to the Brighton Classification Criteria [28]. This left, a total of 72
confirmed cases for inclusion in the study (Fig 1). The date when a case was first referred for a
MSLT was defined as the index date.
Controls were selected to match each case on age, gender, index date (so that the control did
not have an MSLT-referral or narcolepsy diagnosis before its matched case), and county of resi-
dence. These were randomly selected from the Swedish Total Population Register, held by Sta-
tistics Sweden [29]. Four matched controls per case were invited to participate in the study. Of
these, 251 individuals accepted the invitation (1057 did not respond, 152 refused participation,
Fig 1. Flowchart to show case and control identification.
doi:10.1371/journal.pone.0154296.g001
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a further 156 were excluded, as they were not matched to cases that agreed to be part of the
study, and four subsequently dropped out). (Fig 1).
Ethical approval
This study was approved by the regional ethics committee in Stockholm and written informed
consent was collected from all study participants.
Data collection
Information regarding MSLT referral date and diagnosis date was collected from medical
charts for the cases. Additional information for onset of cataplexy, excessive daytime sleepiness
and Hypocretin-1 measurement in CSF was also available, however due to incomplete/miss-
ing/unknown dates for some cases these variables were excluded from the analysis.
Using a standardised questionnaire, a research nurse collected self-reported information,
via telephone interviews, on previous disease and vaccination history from cases and controls
for the period 1st January 2005 - 31st December 2010. Additional information on methodology
can be found in the ECDC technical report [27]. Due to this long ascertainment period, infor-
mation on self-reported medications and diseases was often incomplete i.e. the answer to sim-
ple yes/no questions regarding use of medication and diseases was missing in up to 45% of
respondents, and the corresponding dates of use/disease were missing for between 73% and
100% (data not shown).
Consequently, self-reported information on diseases and medications was discarded in
favour of register data, with the exception of vaccination status, which was only available
through interview as the registration of vaccinations was not mandatory during the study
period. Information on medication use was collected from the Prescribed Drug Register
(PDR), which includes data on drugs prescribed in Sweden from July 2005 including prescrip-
tion date, dosage and duration, expenditure and reimbursements. All drugs are classified
according to the World Health Organisation Anatomical Therapeutic Chemical (ATC) Classi-
fication [30]. Disease information was collected from the National Patient Registers (NPR),
which contains information on diagnoses in Swedish hospitals from specialised outpatient care
from 2001 and inpatient care since 1987. The registers are managed by the National Board of
Health and Welfare [31] and linkage of participant data to the registers is possible through
their unique personal identification numbers [32].
Exposures
Data on the following ATC codes were collected to investigate whether prescription history
was a risk factor for narcolepsy before A(H1N1)pdm09 vaccination: nervous system disorders
(N), obstructive airway diseases (R03), antibacterial (J01), anti-inflammatory/anti-rheumatic
drugs, non-steroid (M01A), antiviral (J05), immunosuppressant (L04) and diabetes (A10). Pre-
scriptions for psychostimulants, agents used for ADHD treatment and nootropics (ATC
N06BA01, N06BA03, N06BA04, N06BA07, and N06BA09) were used as a proxy for ADHD
diagnosis in this study. The ADHD subcategory was created from prescriptions for N and
therefore prescriptions for ADHD are included in the total number of prescriptions for N. Pre-
scription issue date is used as a proxy for date of drug use.
Data on the following diagnosis codes, based on the International Classification of Disease
(ICD) version 10, were collected from the NPR to investigate whether diagnosis history was a
risk factor for narcolepsy before A(H1N1)pdm09 vaccination: nervous system disorders (G00-
473, G475-99 –excluding narcolepsy (G474)), mental and behavioural disorders (F00-99), bac-
terial diseases (A30-49), neoplasms (C00-99), respiratory diseases (J00-99), viral infections of
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the CNS (A80-99), other infections of CNS (B25-34), other bacterial, viral and other infectious
agents (B95-99) and diabetes mellitus (E10-14).
To investigate if a combination of prescription (ATC) and disease (ICD10) history was a
risk factor for narcolepsy before A(H1N1)pdm09 vaccination, four combined exposure groups
were created: a) nervous system disorders (ATC N and/or ICD10 G00-473, 475–99); b) bacte-
rial diseases (ATC J01/ ICD10 A30-49); c) respiratory diseases (ATC R03/ICD10 J00-99) and;
d) viral diseases (ATC J05/ ICD10 A80-99, B25-34).
For the purpose of measuring a crude measure of intensity a multiple prescription/diagnosis
variable was created. This variable took into account that participants may have received one
or more prescriptions and/or diagnoses over the exposure period in more than one prescrip-
tion or diagnosis category.
Exposure windows
Disease history was studied as a risk factor for narcolepsy over three different exposure win-
dows (Fig 2): 1) prescription (ATC) and diagnosis (ICD10) history before the index date. This
period covered at least 5-years prior to the index date from the first prescription in the PDR
(2005), or diagnosis date in the inpatient (1987) or outpatient (2001) registers respectively; 2)
prescription history during the ‘vaccination period’ defined as six months before each case/
control was first vaccinated with A(H1N1)pdm09 vaccine until one month after, with the
exception of acute infections, e.g. prescriptions for antibacterials (ATC J01) and antivirals
(ATC J05), where this period was shortened to two weeks before and after, as these infections
are self-limiting; 3) prescription and diagnosis history before A(H1N1)pdm09 vaccination—
again covering at least 5-years prior to vaccination, from first prescription or diagnosis.
The self-reported A(H1N1)pdm09 vaccination dates were incomplete for some cases and
controls. In such instances the day of month was assigned the 15th, missing months in 2009
were assigned to November i.e. the middle of October-December, and missing months in 2010
were assigned to January i.e. the middle of the overall vaccination period of October
2009-March 2010.
Statistical analysis
Conditional logistic regression was used to estimate odds ratios (OR) together with 95% confi-
dence intervals (95% CI). Given the rarity of narcolepsy in the general population, ORs were
Fig 2. Exposure windows. 1. Prescription (ATC) and diagnosis (ICD10) history before index date (MSLT-referral date). Ever was defined as after the first
date in either the inpatient register (1987), outpatient register (2001) or prescribed drug register (2005) and prior to the index date. 2. Prescription (ATC) and
diagnosis (ICD10) history during the vaccination period. This period extended to six months before to one month after A(H1N1)pdm09 vaccination (specific to
each individual). For acute infections (bacterial (ATC J01) and viral (ATC J05)) this period was shortened to two weeks before to two weeks after vaccination.
3. Prescription (ATC) and diagnosis (ICD10) history before vaccination. Ever was defined as after the first date in either the PDR (2005), inpatient register
(1987) or outpatient register (2001) and prior to the vaccination date.
doi:10.1371/journal.pone.0154296.g002
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interpreted as the relative risk (RR) of narcolepsy [33]. Each exposure was assessed as a covari-
ate in a univariate model, which was controlled for the joint effect of the matching variables
through conditioning. The significance level was 0.05 and all tests were two sided. The analyses
were performed using SAS version 9.4.
Three analyses were performed. First, a full data analysis investigating disease history as a
risk factor for narcolepsy. In this model, all cases and controls were included regardless of vac-
cination status and timing of vaccination, i.e. whether the index date was before A(H1N1)
pdm09 vaccination or after. The exposure window of interest in this analysis was prescriptions
or diagnoses before the index date (exposure window 1, Fig 2).
Second, a vaccinated-only analysis i.e. cases and controls vaccinated before the index date,
to determine if disease history is an effect modifier for vaccination status. The periods of inter-
est were prescriptions and diagnosis history before the index date (exposure window 1), pre-
scription history during the vaccination period (exposure window 2) and prescription and
diagnosis history before vaccination (exposure window 3, Fig 2).
Third, a case-only analysis was used to compare vaccinated cases with an index date before
vaccination to vaccinated cases with an index date after vaccination. This analysis is based on
the assumption that for a rare disease, with somewhat unspecific symptoms, there may be an
extended history of misdiagnoses/treatment prior to the correct diagnosis, leading to con-
founding by indication. The exposure windows of interest in this analysis included prescription
and diagnosis history during the vaccination period and before vaccination (exposure window
2 and 3 respectively, Fig 2).
Sensitivity analyses using the diagnosis date of narcolepsy as the index date instead of
MSLT-referral date were carried out for all three analyses.
Results
The majority of cases (71%) were under 20 years of age and a larger proportion of cases were
vaccinated compared to the controls (94% vs. 74%) (Table 1).
In the full data analysis several prescription and diagnosis categories before the index date
were associated with an increased risk of narcolepsy (Table 2 and exposure window 1, Fig 2).
Statistically significant effects were found for prescriptions of drugs for nervous system disor-
ders (OR = 3.6, 95% CI 1.8–7.1), prescriptions for ADHD (OR = 4.5, 95% CI 1.4–14.7), diagno-
sis of nervous system disorders (OR = 8.8, 95% CI = 2.7–28.6) and diagnoses of mental and
behavioural disorders (OR = 3.8, 95% CI 1.6–8.8), Further statistically significant findings were
found for prescriptions for obstructive airway diseases, multiple prescriptions and multiple dis-
ease diagnoses and combined prescriptions/diagnoses for nervous system disorders (Table 2).
Table 1. Characteristics of the study population.
Characteristics Case (N = 72) Control (N = 251)
N (%) N (%)
Sex (male) 35 (48.6) 124 (49.4)
H1N1 vaccination 68 (94.4) 186 (74.1)
Age (years)
<5 4 (5.6) 18 (6.1)
6–10 13 (18.1) 49 (19.5)
11–15 17 (23.6) 60 (23.9)
16–20 17 (23.6) 51 (20.3)
21–30 9 (12.5) 32 (10.9)
30+ 12 (16.7) 41 (14.0)
doi:10.1371/journal.pone.0154296.t001
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Table 2. Full case-analysis for prescription (ATC) history and diagnosis (ICD10) history before index date and vaccinated-only analysis for pre-
scription and diagnosis history before index date on the risk of developing narcolepsy.
Characteristics Full-case analysis* Vaccinated-only analysis**
Cases Controls OR (95% CI) P-value Cases Controls OR (95% CI) P-
value
(N = 72) (N = 251) N = 54) (N = 85)
N (%) N (%) (N (%) N (%)
Prescriptions (ATC) before index date
Nervous system disorders (N) 21
(29.17)
30 (11.95) 3.55 (1.77–
7.13)
0.0004 15
(27.78)
19
(22.35)
1.34 (0.61–
2.93)
0.47
ADHD (N06BA) 7 (9.72) 5 (1.99) 4.49 (1.37–
14.71)
0.01 6 (11.11) 4 (4.71) 2.56 (0.68–
9.42)
0.17
Obstructive airway diseases (R03) 13
(18.05)
31 (12.35) 2.14 (1.00–
4.57)
0.049 11
(20.37)
15
(17.65)
1.19 (0.50–
2.84)
0.69
Antibacterial (J01) 43
(59.72)
127
(50.60)
1.58 (0.90–
2.77)
0.12 32
(59.26)
67
(78.82)
0.39 (0.18–
0.83)
0.01
Anti-inﬂammatory/rheumatic drugs, non-
steroid (M01A)
7 (9.72) 30 (11.95) 0.84 (0.33–
2.14)
0.71 5 (9.26) 15
(17.65)
0.48 (0.16–
1.40)
0.18
Antiviral (J05) 2 (2.78) 6 (2.39) 1.23 (0.24–
6.23)
0.80 2 (3.70) 3 (3.53) 1.05 (0.17–
6.51)
0.96
Multiple prescriptions 57
(79.17)
142
(56.57)
3.30 (1.72–
6.33)
0.0003 43
(79.63)
73
(85.88)
0.64 (0.26–
1.58)
0.34
Diagnoses (ICD10) before index date
Nervous system disorders (G00-473, 475–99) 10
(13.89)
6 (2.40) 8.76 (2.68–
28.61)
0.0003 7 (12.96) 3 (3.53) 4.07 (1.01–
16.50)
0.049
Mental and behavioural disorders (F00-99) 13
(18.06)
14 (5.58) 3.76 (1.60–
8.81)
0.002 10
(18.52)
7 (8.24) 2.53 (0.90–
7.12)
0.08
Bacterial diseases (A30-49) 1 (1.39) 1 (0.40) 7.48 (0.47–
119.82)
0.15 1 (1.85) 1 (1.18) 1.59 (0.10–
25.88)
0.75
Neoplasms (C00-99) 1 (1.39) 3 (1.20) 1.36 (0.12–
15.98)
0.81 1 (1.85) 1 (1.18) 1.59 (0.10–
25.88)
0.75
Respiratory disease (J00-99) 15
(20.83)
58 (23.12) 0.98 (0.48–
1.99)
0.96 12
(22.22)
27
(31.76)
0.61 (0.28–
1.35)
0.22
Multiple diagnoses 31
(43.06)
71 (28.29) 2.39 (1.30–
4.39)
0.005 26
(48.15)
34 (40.0) 1.39 (0.70–
2.77)
0.35
Prescriptions (ATC) &/or diagnoses (ICD10) before index date
Nervous system disorders (N/G00-473, 475–
99)
27
(37.50)
33 (13.15) 3.96 (2.17–
7.23)
<0.0001 20
(37.04)
21
(24.71)
1.79 (0.86–
3.76)
0.12
Bacterial disease (J01/A30-49) 43
(59.72)
126
(50.20)
1.47 (0.86–
2.50)
0.16 32
(59.26)
67
(78.82)
0.39 (0.18–
3.76)
0.12
Respiratory diseases (R03/J00-99) 22
(37.50)
67 (26.69) 1.21 (0.68–
2.15)
0.52 19
(35.19)
31
(36.47)
0.95 (0.46–
1.93)
0.88
Viral diseases (J05/A80-99, B25-34) 2 (2.78) 7 (2.79) 0.10 (0.20–
4.90)
0.10 2 (3.70) 4 (4.71) 0.78 (0.14–
4.41)
0.78
*Full case-model includes all cases and controls, regardless of vaccination status and timing of vaccination.
** Case exclusions in vaccinated-only analysis: 4 unvaccinated, 2 missing vaccination date, 1 missing referral date, 10 referred before vaccination, 1
ambiguous vaccination date. Control exclusions: 64 unvaccinated, 79 missing vaccination dates, 3 matched to case with no referral date, 20 matched with
cases referred before vaccination. Prescription (ATC) and diagnoses (ICD10) categories investigated but insufﬁcient data to compute from model:
Prescriptions before index date; immunosuppressant (L04) and diabetes (A10). Diagnoses before index date; viral infections of CNS (A80-99), other viral
infections of CNS (B25-34), other bacterial, viral and other infectious agents (B95-99) and diabetes mellitus (E10-14).
doi:10.1371/journal.pone.0154296.t002
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In the second, vaccinated-only analysis, nearly all statistically significant associations from
the full data analysis were no longer significant (Table 2). Only diagnoses of nervous system
disorders before index date (exposure window 1, Fig 2) appeared marginally significant
(OR = 4.1 95% CI 1.01–16.5); this is not only due to lower power and wider confidence inter-
vals, but we also found a consistent reduction of the estimated relative risks. In addition, it was
found that the prescriptions of drugs for antibiotics before index date had a significant protec-
tive effect (OR = 0.4, 95% CI 0.2–0.8).
Furthermore, in the second vaccinated-only analysis, no statistically significant associations
were found for prescriptions or diagnoses during the vaccination period (exposure window 2,
Fig 2) or diagnoses or multiple prescription/diagnoses before vaccination (exposure window 3,
Fig 2). The only statistically significant effect was observed for prescriptions of drugs for ner-
vous system disorders before vaccination, which was protective (OR = 0.3 95% CI 0.1–1.0)
(Table 3).
The third and final case-only analysis compared vaccinated cases with an index date before
vaccination to vaccinated cases with an index date after vaccination (Table 4): Large significant
effects were observed for prescriptions of drugs for nervous system disorders (OR = 26.0, 95%
CI 4.0–170.2), ADHD (OR = 35.3, 95% CI 3.4–369.9) and anti-inflammatory/rheumatic drugs
(OR = 13.3, 95% CI 1.1–163.5) during the vaccination period (exposure window 2, Fig 2). Mul-
tiple prescriptions were also statistically significant (Table 4).
Large significant effects were found for prescriptions for nervous system disorders
(OR = 17.0 95% CI 3.1–93.1) and ADHD (OR = 53.0 95% CI 5.1–547.3) before vaccination
(Exposure window 3, Fig 2). A statistically significant effect was observed for diagnoses of ner-
vous system disorders before vaccination, which was protective (OR = 0.04 95% CI 0.0004–
0.48) (Table 4).
Using the diagnosis date as the index date rather than MSLT-referral date the same patterns
of statistical significance in the sensitivity analysis were found (data not shown).
Discussion
Three analyses of the risk of narcolepsy based on vaccination status and prior disease history
were undertaken using data from a nationwide population-based case-control study. No evi-
dence was found that prior disease history represented a risk factor for narcolepsy and it is
probable that statistically significant associations found in the initial full data analysis are likely
a result of confounding by indication.
In the first full data analysis, disease history before the index date (exposure window 1) was
investigated as a risk factor for narcolepsy. An increased risk of narcolepsy for prescriptions of
drugs for nervous system disorders, ADHD and obstructive airway diseases and prior diagnosis
of nervous system disorders and mental and behavioural disorders was found. It is hypothe-
sised that the significant effect observed for ADHD could be explained by potential misdiagno-
sis, which could then be a contributory factor for the statistically significant effects observed for
prescriptions for nervous system disorders and diagnoses of mental and behavioural disorders.
When comparing the overall neurological/psychiatric disorders between cases and controls in
our study, only cases were previously diagnosed with sleep related diseases such as hypersom-
nia and sleep apnoea, which would support the idea that early cases of narcolepsy may have
been initially misdiagnosed (data not shown).
Oosterloo et al [34] have showed that there is a risk of misdiagnosis between hypersomnias
of central origin, e.g. narcolepsy and ADHD in adults, since both share symptoms such as
problems with concentration and attention. Furthermore, Modestino et al [35] reported that
adults with narcolepsy often displayed ADHD symptomatology in childhood, supporting the
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possibility that early cases in our study may have been initially misdiagnosed and prescribed
ADHDmedications. There is also the potential for overlap in treatment between ADHD and
narcolepsy, with some medications such as Adderall1 (amphetamine, dextroamphetamine
mixed salts) being used to treat both conditions [36]. Together, such factors offer a potential
explanation for the statistically significant effect observed for the prescription of drugs for
ADHD in the full data analysis.
While a growing number of studies have looked at streptococcal infection and H1N1 infec-
tion as a risk factor for narcolepsy [21–25], we found no evidence for such an association in
our study. Due to the small study size, it was not possible to look at individual disease codes in
the broader ATC & ICD10 categories, resulting in a risk of type II statistical error due to lack of
power. In addition, we based our analysis on health care register data, which may have resulted
in a registration of fewer bacterial and viral infections being reported, with people only seeking
Table 3. Vaccinated-only analysis investigating prescription (ATC) history during the vaccination period and ever before A(H1N1)pdm09 vaccina-
tion and diagnosis (ICD10) history ever before vaccination and prior to index on the risk of developing narcolepsy.
Characteristics Cases* Controls** Odds ratio (95% CI) P-value
N = 54 (%) N = 85 (%) Unadjusted
Prescriptions (ATC) in vaccination period
Nervous system disorders (N) 2 (3.70) 8 (9.41) 0.37 (0.08–1.81) 0.22
ADHD (N06BA) 1 (1.85) 4 (4.71) 0.38 (0.04–3.51) 0.40
Obstructive airway disease (R03) 3 (5.56) 5 (5.88) 0.94 (0.22–4.11) 0.94
Anti-inﬂammatory/rheumatic drugs, non-steroid (M01A) 1 (1.85) 4 (4.71) 0.52 (0.05–5.09) 0.57
Multiple prescriptions 6 (11.11) 14 (16.47) 0.63 (0.23–1.77) 0.38
Prescriptions (ATC) before vaccination
Nervous system disorders (N) 3 (5.56) 15 (17.65) 0.28 (0.08–1.0) 0.049
ADHD (N06BA) 1 (1.85) 3 (3.53) 0.52 (0.05–5.09) 0.57
Obstructive airway diseases (R03) 10 (18.52) 14 (16.47) 1.15 (0.47–2.82) 0.76
Antibacterial (J01) 30 (55.56) 58 (68.24) 0.58 (0.29–1.18) 0.13
Antiviral (J05) 1 (1.85) 3 (3.53) 0.52 (0.05–5.09) 0.57
Anti-inﬂammatory/rheumatic drugs, non-steroid (M01A) 5 (9.26) 13 (15.29) 0.57 (0.19–1.69) 0.31
Multiple prescriptions 35 (64.81) 66 (77.65) 0.53 (0.25–1.13) 0.10
Diagnoses (ICD10) before vaccination
Nervous system disorders (G00-473, 475–99) 1 (1.85) 3 (3.53) 0.52 (0.05–5.09) 0.57
Mental behavioural disorders (F00-99) 4 (4.71) 7 (8.24) 0.89 (0.25–3.20) 0.86
Respiratory disease (J00-99) 11 (20.37) 26 (30.59) 0.58 (0.26–1.30) 0.19
Bacterial disease (A30-49) 1 (1.85) 1 (81.12) 1.59 (0.10–25.88) 0.75
Multiple diagnoses 18 (33.33) 33 (38.82) 0.79 (0.39–1.61) 0.51
Prescriptions (ATC) &/or diagnoses (ICD10) before vaccination
Nervous system disorders (N/ G00-473, 475–99) 4 (7.41) 17 (20.0) 0.32 (0.10–1.01) 0.052
Bacterial disease (J01/A30-49) 30 (55.56) 58 (68.24) 0.58 (0.29–1.12) 0.13
Respiratory diseases (R03/J00-99) 17 (31.48) 29 (34.12) 0.89 (0.43–1.84) 0.75
Viral disease (J05/A80-99, B25-34) 1 (1.85) 4 (4.71) 0.38 (0.04–3.51) 0.40
*Case exclusions: 4 unvaccinated, 2 missing vaccination date, 1 missing referral date, 10 referred before vaccination, 1 ambiguous vaccination date.
**Control exclusions: 64 unvaccinated, 79 missing vaccination dates, 3 matched to cases with no referral date, 20 matched with cases referred before
vaccination. Prescription (ATC) and diagnoses (ICD10) categories investigated but insufﬁcient data to compute from the model: Prescriptions in the
vaccination period; antibacterial (J01), antiviral (J05), immunosuppressant (L04) and diabetes (A10). Prescriptions before index date; immunosuppressant
(L04) and diabetes (A10). Diagnoses before vaccination; neoplasms (C00-99), viral infections of CNS (A80-99), other infections of CNS (B25-34), other
bacterial, viral and other infectious agents (B95-99), and diabetes mellitus (E10-14).
doi:10.1371/journal.pone.0154296.t003
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medical care when an infection is severe and longer lasting. This may have resulted in an
underestimation of disease exposure and be a potential reason for the lack of associations
found here.
A second vaccinated-only analysis was carried out excluding cases or controls that were
unvaccinated or had an index date (MSLT-referral) prior to vaccination. Interestingly, nearly
all statistically significant associations from the full data analysis were no longer significant and
there was a consistent reduction of the estimated relative risks.
As this second analysis had excluded cases with an index date before vaccination (early
cases), it was speculated that such cases could be driving the associations observed in the full
data analysis: if early cases presented with symptoms before vaccination then they most proba-
bly would have received more prescriptions within the vaccination period (and before index
date) than those referred after vaccination (vaccine-associated cases). Additionally, the diag-
nostic time frame is shorter in vaccine-associated cases relative to naturally occurring cases,
which may have resulted in fewer incorrect prescriptions and diagnoses in cases with an index
date after vaccination. In addition, due to an increased awareness of narcolepsy following A
Table 4. Case-only analysis investigating prescription (ATC) history during the vaccination period and before index date and diagnosis (ICD10)
history before index date on risk of developing narcolepsy.
Case characteristics Referral before vaccination Referral after vaccination Odds ratio (95% CI) P-value
N = 64* N = 10 (%) N = 54 (%) Unadjusted
Prescriptions (ATC) in vaccination period
Nervous system disorders (N) 5 (50.0) 2 (3.70) 26.00 (3.97–170.21) 0.0007
ADHD (N06BA) 4 (40.0) 1 (1.85) 35.33 (3.38–369.85) 0.003
Obstructive airway diseases (R03) 1 (10.0) 3 (5.56) 1.89 (0.18–20.24) 0.60
Anti-inﬂammatory/rheumatic drugs, non-steroid (M01A) 2 (20.0) 1 (1.85) 13.25 (1.07–163.52) 0.04
Multiple prescriptions 5 (50.0) 6 (11.11) 8.00 (1.78–35.94) 0.007
Prescriptions (ATC) before vaccination
Nervous system disorders (N) 5 (50.0) 3 (5.56) 17.00 (3.10–93.12) 0.001
ADHD (N06BA) 5 (50.0) 1 (1.85) 53.00 (5.13–547.26) 0.0009
Obstructive airway diseases (R03) 1 (10.0) 10 (18.52) 0.49 (0.06–4.31) 0.52
Anti-inﬂammatory/rheumatic drugs, non-steroid (M01A) 2 (20.0) 5 (9.26) 2.45 (0.40–14.85) 0.33
Antibacterial (J01) 6 (60.0) 30 (55.56) 1.20 (0.30–4.74) 0.79
Multiple prescriptions 7 (70.0) 35 (64.81) 1.27 (0.29–5.47) 0.75
Diagnoses (ICD10) before vaccination
Nervous system disorders (G00-473, 475–99) 3 (30.0) 1 (1.85) 0.04 (0.004–0.48) 0.01
Mental and behavioural disorders (F00-99) 3 (30.0) 4 (7.71) 0.19 (0.03–1.02) 0.052
Respiratory diseases (J00-99) 1 (10.0) 11 (20.37) 2.30 (0.26–20.15) 0.45
Multiple diagnoses 4 (40.0) 18 (33.34) 0.75 (0.19–3.00) 0.68
Prescriptions (ATC) &/or diagnoses (ICD10) before vaccination
a) Nervous system disorders (N/ G00-473, 475–99) 6 (60.0) 4 (7.71) 18.75 (3.70–95.14) 0.0004
b) Bacterial diseases (J01/A30-49) 6 (60.0) 30 (55.56) 1.20 (0.30–4.74) 0.79
c) Respiratory diseases (R03/J00-99) 1 (10.0) 17 (31.48) 0.24 (0.03–2.06) 0.19
*Excluding 4 unvaccinated cases, 2 cases missing vaccination date, 1 case no referral date, 1 case with ambiguous vaccination date.
Prescription (ATC) and diagnoses (ICD10) categories investigated but insufﬁcient data to compute from the model: Prescriptions during vaccination
period; antibacterial (J01) antiviral (J05), immunosuppressant (L04) and diabetes (A10), Prescriptions (ATC) before index date; antiviral (J05),
immunosuppressant (L04) and diabetes (A10). Diagnoses before index date; bacterial diseases (A30-49), neoplasms (C00-99), viral infections of CNS
(A80-99), other infections of CNS (B25-34), other bacterial, viral and other infectious agents (B95-99), and diabetes mellitus (E10-14). Prescriptions &/or
diagnoses before index date; viral disease (J05/A80-99, B25-34).
doi:10.1371/journal.pone.0154296.t004
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(H1N1)pdm09 vaccination, this too could have resulted in less misdiagnosis of vaccine-associ-
ated cases. Such factors could help to explain how early cases might be driving the statistically
significant effects observed in the full data analysis and further indicate that exposure window
1, i.e. disease history before index date, could be contaminated with early misdiagnosis between
the administration of the vaccination and index date.
In order to establish whether there was a difference in disease history between early cases
and cases and vaccine-associated cases, a third analysis was conducted. It was found that early
cases were far more likely to have received prescriptions of drugs for nervous system disorders,
ADHD, anti-inflammatory/rheumatic drugs and multiple prescriptions before and during the
vaccination period. This suggests that the statistically significant effects from the full data anal-
ysis were most likely due to confounding by indication and that disease history before A
(H1N1)pdm09 vaccination is not a risk factor for narcolepsy.
Strengths and limitations
To reduce the effects of confounding, strict definitions were used for inclusion criteria and we
matched cases on age, gender, index date and county of residence. At the time of case ascertain-
ment, Type-1 and Type-2 narcolepsy definitions had not been introduced. Due to incomplete/
missing dates for symptom onset e.g. cataplexy, EDS and hypocretin-1 measurement for some
cases, old case definitions were kept. This is a limitation of the study. However, it is unlikely
that the lack of this information would have changed the results, nor would it have helped us
answer whether previous disease history was a risk factor for narcolepsy. To compensate for
missing dates and reduce recall bias in the self-reported information, we used exposure infor-
mation from the Swedish healthcare registers. The A(H1N1)pdm09 vaccination date was self-
reported however. Although we controlled for self-reported vaccination dates we cannot rule
out the possibility of recall bias, with cases being more likely to remember if and when they
received their vaccination than controls, resulting in an overestimation of exposure in cases.
However, as this study took place shortly after the vaccination campaign we believe this
reduced the potential effects of recall bias. To account for the time between vaccination and
diagnosis, several exposure windows were analysed specific to each individual and based on/
around the date they first received the A(H1N1)pdm09 vaccine, or their index date.
Diagnostic bias was a potential issue in this study as typically, many narcolepsy cases have
an incremental progression of symptoms over several years, which results in a lag between the
onset of symptoms and diagnosis. However, following the vaccination campaign there was an
increased awareness of narcolepsy, which shortened the time between the onset of symptoms
and diagnosis. To reduce the potential for diagnostic bias in this study, the MSLT-referral date
was used as the index date and not the date of diagnosis.
It is of note that the ATC and ICD codes used in this study are only proxies for a number of
diseases and they have broad underlying aetiologies, so while they can provide estimations for
disease history they are not as specific as individual codes. In addition, people are less likely to
seek medical attention for milder infections, which could have resulted in an underestimation
of such exposures in this study. It was unfortunately not possible to look at individual codes in
this study, due to a limited sample size. While lack of power is a limitation in this study, it still
remains one of the larger observational studies to date in Sweden, which looks at the associa-
tion between A(H1N1)pdm09 vaccination and narcolepsy.
Conclusions
The findings from this study do not support that disease history is a risk factor for narcolepsy
after A(H1N1)pdm09 vaccination. However, due to the limited power of this study these
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results require to be confirmed through larger studies to investigate the role of disease history
on the aetiology of narcolepsy. Additional studies are required to explore the possible misdiag-
nosis of narcolepsy in childhood with ADHD and other mental and behavioural disorders, to
determine whether narcolepsy cases are being missed until later years.
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